Lung events hit tivantinib's Asian NSCLC trial but Western Ph III study still on track
This article was originally published in Scrip
Kyowa Hakko Kirin has stopped patient enrolment in the Phase III ATTENTION clinical trial in Asia for the ArQule cancer drug tivantinib due to cases of interstitial lung disease (ILD), but ArQule says the move will not impact its ongoing 1,000-patient Phase III MARQUEE trial being conducted with Daiichi Sankyo in the Americas, Europe and other regions.
You may also be interested in...
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.